Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (17.4%);
- veterinary medicine (12.8%);
- cardiovascular diseases (9.2%);
- neurology (7.4%): primarily drugs used in treating depression and schizophrenia;
- immunology diseases (4.6%);
- other (1%).
Net sales are distributed geographically as follows: the United States (56.5%), Europe (17.2%), Japan (10.2%) and other (16.1%).
- endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (17.4%);
- veterinary medicine (12.8%);
- cardiovascular diseases (9.2%);
- neurology (7.4%): primarily drugs used in treating depression and schizophrenia;
- immunology diseases (4.6%);
- other (1%).
Net sales are distributed geographically as follows: the United States (56.5%), Europe (17.2%), Japan (10.2%) and other (16.1%).
Source: Cofisem - Last Update: 2019-10-31
Key Executives
| Chairman and Chief Executive Officer | |
| Chief Financial Officer | |
| VP, Communication | |
| Human Resources Director |
Source: Cofisem - Last Update: 2019-06-21
Key Figures
| Millenium | 2016 | 2015 | 2014 | 2018 | 2017 |
|---|---|---|---|---|---|
| Net sales | 18,554,192 | 17,449,620 | 17,149,652 | 21,468,714 | 19,996,066 |
| Cost of sales | 4,944,002 | 4,403,955 | 4,312,417 | 5,621,661 | 5,307,093 |
| Payroll | |||||
| Operating income | 3,023,719 | 2,351,305 | 2,325,426 | 3,253,132 | 1,875,344 |
| Income tax | 556,395 | 333,627 | 533,139 | 492,835 | 2,099,598 |
| Net income | 2,393,446 | 2,105,631 | 2,089,981 | 2,825,693 | -178,441 |
| Net consolidated income (Group share) | 2,393,446 | 2,105,631 | 2,089,981 | 2,825,693 | -178,441 |
| Fiscal year end | 12.16 | 12.15 | 12.14 | 12.18 | 12.17 |
| Length of fiscal year (month) | 12 | 12 | 12 | 12 | 12 |
| Currency & Unit | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands | EUR - thousands |
| Account Standards |
Source: Cofisem - Last Update: 2019-10-31
Shareholder information
| Lilly Endowment | |
| Vanguard Group Inc | |
| BlackRock, Inc. | |
| Norinchukin Zenkyoren Asset Mgmt Co. Ltd | |
| PRIMECAP Management Company | |
| State Street Corporation | |
| Wellington Management Company LLP | |
| Blackrock Asset Management Canada Limited | |
| BlackRock Fund Advisors | |
| Geode Capital Management LLC |
Source: Cofisem - Last Update: 2019-06-21
Address
Eli Lilly and Company
Lilly Corporate Center
IN 46285 Indianapolis, Indiana
United States
Phone number: +1 617-225-3226
Fax: +1
https://investor.lilly.com/
Source: Cofisem - Last Update: 2019-10-31
Contact
Philip L. Johnson
Phone number: 1-317-655-6874
johnson_philip_l@lilly.com
Phone number: 1-317-655-6874
johnson_philip_l@lilly.com
Source: Eli Lilly and Company - Last Update: 2019-10-31
Please contact MyQuestion.Italy@euronext.com for Company Profile support.